Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.33 USD
Change Today 0.00 / 0.00%
Volume 0.0
RVALL On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
As of 8:10 PM 06/24/15 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RVALL) Key Developments

REVA Medical, Inc. Releases Initial Clinical Results for Fantom Scaffold

REVA Medical, Inc. released initial clinical data on a subset of patients treated with the Fantom sirolimus-eluting bioresorbable scaffold at the Paris Course on Revascularization (EuroPCR). The FANTOM I pilot clinical trial, which enrolled patients with the Fantom scaffold at two clinical sites in Brazil and Poland, was designed to provide early clinical data on the device. In these patients acute performance was demonstrated with 100% technical and procedural success and no reported Major Adverse Cardiac Events (MACE) to date, with no incidence of ischemic target lesion revascularization (TLR), myocardial infarction (heart attack) or stent thrombosis. REVA is currently enrolling patients in the FANTOM II trial, which is designed to provide the necessary data for a European CE Mark application of Fantom.

Reva Medical, Inc. Expands FANTOM II Clinical Trial to Australia

REVA Medical, Inc. announced that the FANTOM II clinical trial is now enrolling patients with the Fantom sirolimus-eluting bioresorbable scaffold in Australia. This is in addition to previously announced sites in Brazil and Europe. The Fantom scaffold, made from REVA's advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial is enrolling patients to support a European CE Mark application, which is expected to occur by mid-2016.

REVA Medical, Inc. - Shareholder/Analyst Call

2015 annual general meeting of stockholders

REVA Medical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

REVA Medical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company's loss from operations of $4,853,000 compared to $7,272,000 a year ago. Net loss and comprehensive loss was $23,357,000 compared to $7,276,000 a year ago. Net loss per share, basic and diluted was $0.70 compared to $0.22 a year ago. Net cash used for operating activities was $4,962,000 compared to $6,649,000 a year ago. Purchases of property and equipment were $281,000 compared to $216,000 a year ago.

REVA Medical, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

REVA Medical, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the period, the company's net operating cash outflows was $4,961,000. Payment for acquisition of physical non-current assets was $282,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVALL:US $0.33 USD 0.00

RVALL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVALL.
View Industry Companies
 

Industry Analysis

RVALL

Industry Average

Valuation RVALL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.